Keywordsasymmetric dimethylarginine; coronary artery disease; proton pump inhibitors; acute coronary syndrome; atherosclerosis; magnetic resonance imaging; plaque; thrombosis; intraplaque hemorrhage; LDL receptor-related protein-6 (LRP6); normolipidemic; coronary artery disease; familial; endothelial cell dysfunction; artery-to-artery embolism; carotid endarterectomy; cerebral hemodynamic insufficiency; cerebral hyperperfusion; ischemic lesion; meta-analysis; systematic review; coronary calcification; risk factors; atherosclerosis; vulnerable plaques; animal models; genetically modified mice; molecular imaging; carotid endarterectomy; artery-to-artery embolism; plaque imaging; three-dimensional; fast spin echo magnetic resonance; human renal microcirculation; healthy aging; paraffin-embedded sections; three-dimensional imaging; virtual microscopy; acute ischemic stroke; intracranial clot; vascular disease; atherosclerosis; neuroimaging; hyperdense artery sign; biomarker; intravascular ultrasound (IVUS); near-infrared fluorescence (NIRF); atherosclerosis; ex vivo three-dimensional (3D) histology; optical coherence tomography (OCT); confocal fluorescence microscopy; brain vascular disorders; imaging; vascular biology; brain atlas; animal models; molecular imaging; computed tomography (CT); positron emission tomography (PET); magnetic resonance angiography (MRI); photoacoustic imaging (PAI); magnetic resonance angiography (MRA)
